Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis

Abstract

The present invention provides a method of treating or inhibiting at least one of allergic asthma, allergic rhinitis and atopic dermatitis, or of reducing, inhibiting or treating allergy like symptoms. The methods use compositions comprising chlorite, chloride, chlorate and/or sulfate ions.

1 .- 77 . (canceled) 
     
     
         78 . A method of treating a subject suffering from or at risk of developing an allergic reaction to an allergen comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising chlorite wherein the allergen is selected from the group consisting of food, dust mite, pet dander, pollen, mold, plant and hay allergens. 
     
     
         79 . The method of  claim 78 , wherein the food allergen is apple. 
     
     
         80 . The method of  claim 78 , wherein the pollen allergen is birch pollen. 
     
     
         81 . The method of  claim 78 , wherein the plant allergen is hazelnut or willow. 
     
     
         82 . The method of  claim 78 , wherein the administering is effected not more than once every six months, once every year, or once every two years. 
     
     
         83 . The method of  claim 78 , wherein the pharmaceutical composition further comprises chlorate. 
     
     
         84 . The method of  claim 78 , wherein the pharmaceutical composition comprises WF10. 
     
     
         85 . The method of  claim 78 , wherein the pharmaceutical composition consists of WF10. 
     
     
         86 . The method of  claim 78 , wherein the pharmaceutical composition comprises about 40 to about 80 mMol chlorite (ClO 2   − ) per liter. 
     
     
         87 . The method of  claim 78 , wherein the pharmaceutical composition comprises about 60 mMol chlorite (ClO 2   − ) per liter. 
     
     
         88 . The method of  claim 78 , wherein the pharmaceutical composition is administered in a range from about 0.01 mL/kg to 2 mL/kg body weight of the subject. 
     
     
         89 . The method of  claim 88 , wherein the pharmaceutical composition is administered in a range from about 0.1 mL/kg to about 1.5 mL/kg body weight of the subject. 
     
     
         90 . The method of  claim 88 , wherein the pharmaceutical composition is administered at about 0.5 mL/kg body weight of the subject. 
     
     
         91 . The method of  claim 78 , wherein chlorite (ClO 2   − ) is administered in an amount compared to that administered by an intravenous infusion of WF10 dosed between about 0.01 mL/kg and 2.0 mL/kg body weight of the subject. 
     
     
         92 . The method of  claim 78 , wherein chlorite (ClO 2   − ) is administered in an amount compared to that administered by an intravenous infusion of WF10 dosed between about 0.0425 mg/kg and 8.50 mg/kg body weight of the subject. 
     
     
         93 . The method of  claim 78 , wherein the pharmaceutical composition is diluted with saline in water prior to administration. 
     
     
         94 . The method of  claim 78 , wherein the pharmaceutical composition is diluted with at least 250 mL of saline in water and administered over 60-90 minutes. 
     
     
         95 . The method of  claim 78 , wherein the subject is an adult and the chlorite (ClO 2   − ) is administered in an amount comparable to that administered by an intravenous infusion of WF10 dosed between 50 to 75 mL to the subject regardless of body weight. 
     
     
         96 . The method of  claim 78 , wherein the subject is an adult and the chlorite (ClO 2   − ) is administered in an amount comparable to that administered by an intravenous infusion of WF10 dosed between 5 to 50 mg to the subject regardless of body weight. 
     
     
         97 . The method of  claim 78 , wherein the pharmaceutical composition is administered within a 7 day period. 
     
     
         98 . The method of  claim 97 , wherein the pharmaceutical composition is administered to the subject in accordance with a treatment selected from the group consisting of (i) 1 to 6 daily infusions within a 7 day period, (ii) 2 to 5 daily infusions within a 7 day period, (iii) 3 to 5 daily infusions within a 7 day period, (iv) 4 to 5 daily infusions within a 7 day period, and (v) daily for 5 consecutive days. 
     
     
         99 . The method of  claim 78 , wherein the pharmaceutical composition is administered within a 7 to 28 day period. 
     
     
         100 . The method of  claim 99 , wherein the pharmaceutical composition is administered to the subject in accordance with a treatment selected from the group consisting of (i) 1 to 6 daily infusions within a 7 to 28 day period, (ii) 2 to 5 daily infusions within a 7 to 28 day period, (iii) 3 to 5 daily infusions within a 7 to 28 day period, and (iv) 4 to 5 daily infusions within a 7 to 28 day period. 
     
     
         101 . The method of  claim 99 , wherein the pharmaceutical composition is administered at different doses on different treatment days. 
     
     
         102 . The method of  claim 78 , further comprising administering to the subject at least one agent selected from the group consisting of anti-IgE, anti-TNFalpha antibodies, anti-inflammatory agents, steroids, anti-allergic agents, and anti-asthma agents. 
     
     
         103 . The method of  claim 78 , wherein the subject is a mammal. 
     
     
         104 . The method of  claim 78 , wherein the subject is a human. 
     
     
         105 . The method of  claim 78 , wherein the composition is administered intravenously, orally, parenterally, topically, via transdermal therapeutic systems, rectally, intranasally, by inhalation or by eye drops. 
     
     
         106 . The method of  claim 78 , wherein the patient is suffering from or at risk of developing hay fever. 
     
     
         107 . The method of  claim 78 , wherein the patient is suffering from or at risk of developing farmer's lung. 
     
     
         108 . The method of  claim 78 , wherein the patient is suffering from or at risk of developing allergic asthma, allergic rhinitis and atopic dermatitis. 
     
     
         109 . The method of  claim 78 , wherein the administering is effected one time.